OR WAIT 15 SECS
The new service offering includes feasibility studies, process and analytical development, and scale-up from milligram to gram quantities required for pilot and subsequent commercial scale.
EMD Millipore, the life-science division of Merck KGaA, Darmstadt, Germany, announced that it has teamed up with celares GmbH to provide pegylation services for drug developers of protein-based therapeutics and biosimilars. This new service offering includes feasibility studies, process and analytical development, and scale-up from milligram to gram quantities required for pilot and subsequent commercial scale.
The attachment of polyethylene glycol to a molecule, known as pegylation, can improve the pharmacological and physicochemical properties of peptide and protein therapeutics as well as reduce side effects. Pegylation can also be used to enhance protein stability, bioavailability, and solubility, which are common challenges in delivering biologic therapeutics.
Through the alliance with celares GmbH, EMD Millipore can now expand its service portfolio to include conjugation, which will further help customers optimize their biologic or biosimilar drug products and speed up development timelines.
The new service offering will leverage EMD Millipore’s broad range of functionalized PEG products of different molecular weight and activation chemistry, as well as buffers, solvents and excipients, unit operations employed during the pegylation process, and subsequent purification including tangential and normal flow filtration and chromatography.
Source: EMD Millipore